Curated News
By: NewsRamp Editorial Staff
June 17, 2026
GeoVax's Gedeptin Platform Aims to Overcome Cold Tumor Resistance in Immunotherapy
TLDR
- GeoVax's Gedeptin enhances checkpoint inhibitor efficacy, offering a competitive edge in overcoming tumor resistance.
- Gedeptin uses intratumoral gene-directed enzyme prodrug therapy to convert fludarabine into a local cytotoxic agent.
- Gedeptin aims to improve cancer immunotherapy responses, potentially saving more lives by turning cold tumors hot.
- Intriguingly, Gedeptin's bystander killing effect destroys tumor cells and activates systemic immunity against distant tumors.
Impact - Why it Matters
This news matters because it addresses a fundamental challenge in cancer immunotherapy: many tumors do not respond to checkpoint inhibitors due to a lack of immune activation. Gedeptin's ability to convert 'cold' tumors into 'hot' ones could expand the number of patients who benefit from existing immunotherapies like PD-1 inhibitors, potentially improving outcomes for millions with solid tumors. For patients with head and neck cancer and other resistant cancers, this approach offers hope for more effective combination treatments, reducing the burden of disease and improving survival rates.
Summary
GeoVax Labs, Inc. (Nasdaq: GOVX) is making strides in cancer immunotherapy with its Gedeptin® platform, designed to enhance immune checkpoint inhibitor activity and address resistance in solid tumors. The company recently highlighted a peer-reviewed study published in JCI Insight, titled "Broadening Activity of Checkpoint Blockade Agents by Intratumoral Nucleoside Cleavage," which supports Gedeptin's potential to convert immunologically "cold" tumors—those with low immune activity—into responsive ones. This is crucial because many tumors fail to respond to checkpoint inhibitors like PD-1/PD-L1 blockers due to limited immune infiltration and suppressive microenvironments. GeoVax's Chairman and CEO David Dodd emphasized in an Onco'Zine commentary, "The Cold Tumor Barrier: Why Promising Oncology Therapies Fail In Vivo – and What It Will Take to Overcome It," that overcoming this barrier is a major opportunity in oncology. Gedeptin uses a gene-directed enzyme prodrug therapy (GDEPT) approach, delivering a purine nucleoside phosphorylase (PNP) enzyme via an adenoviral vector that converts the prodrug fludarabine into a localized cytotoxic compound, destroying tumor cells while remodeling the microenvironment and activating immune responses.
The company plans a neoadjuvant study in recurrent head and neck squamous cell carcinoma (HNSCC), combining intratumoral Gedeptin with PD-1 immunotherapy and standard care in patients eligible for curative surgery. This setting is ideal because tumors are accessible, checkpoint inhibitors are already standard, and unmet need persists. GeoVax sees Gedeptin as a complement, not a competitor, to checkpoint inhibitors, aiming to improve responses where they fall short. The broader potential extends to multiple solid tumors where checkpoint inhibitors are used but response rates are suboptimal. With growing industry focus on immune-priming strategies, Gedeptin could play a differentiated role in next-generation combination therapies.
GeoVax, also developing GEO-MVA for mpox and smallpox, maintains a robust intellectual property portfolio and seeks strategic partnerships. The company's forward-looking statements highlight risks inherent in clinical development, but the emerging data suggest Gedeptin could address a critical gap in oncology: converting cold tumors to hot ones. For more information, visit www.geovax.com.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, GeoVax's Gedeptin Platform Aims to Overcome Cold Tumor Resistance in Immunotherapy
